异烟酰乙酸乙酯 | 26377-17-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酯及其衍生物
• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 异烟酰乙酸乙酯
• 中文别名: 3-氧代-3-(4-吡啶基)丙酸乙酯
• 英文名称: ethyl 3-oxo-3-(4-pyridyl)propanoate
• 英文别名: ethyl 3-oxo-3-(pyridin-4-yl)propanoate；Ethyl isonicotinoylacetate；ethyl 3-oxo-3-pyridin-4-ylpropanoate
• CAS: 26377-17-3
• 化学式: C₁₀H₁₁NO₃
• mdl: MFCD00094021
• 分子量: 193.202
• InChiKey: PCJNYGPKMQQCPX-UHFFFAOYSA-N

物化性质

• 熔点：
  53-59 °C
• 沸点：
  169°C/4mmHg(lit.)
• 密度：
  1.155
• 溶解度：
  溶于甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.3
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  存放在室温、干燥且密封的环境中。

SDS

Name:	Ethyl Isonicotinoylacetate Material Safety Data Sheet
Synonym:	None
CAS:	26377-17-3

Section 1 - Chemical Product MSDS Name:Ethyl Isonicotinoylacetate Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
26377-17-3	Ethylisonicotinoyl Acetate	100 %	247-635-1

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
May cause eye irritation. The toxicological properties of this material have not been fully investigated.
Skin:
May cause skin irritation. The toxicological properties of this material have not been fully investigated.
Ingestion:
May cause irritation of the digestive tract. Ingestion of large amounts may cause gastrointestinal irritation. The toxicological properties of this substance have not been fully investigated.
Inhalation:
May cause respiratory tract irritation. The toxicological properties of this substance have not been fully investigated.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid if cough or other symptoms appear.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation.
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 26377-17-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Negligible.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 56 - 59 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula:
Molecular Weight: 193.20

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
High temperatures, incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, irritating and toxic fumes and gases, carbon dioxide.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 26377-17-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethylisonicotinoyl Acetate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 26377-17-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 26377-17-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 26377-17-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  异烟酰乙酸乙酯 在 phosphorous oxychloride 、 甲烷磺酸 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 DMF (N,N-dimethyl-formamide) 、 水 为溶剂， 反应 9.42h， 生成 2-[5-(2,6-dimethoxyphenyl)-3,6-dihydro-2H-pyridin-1-yl]-3-methyl-6-pyrimidin-4-yl-3H-pyrimidin-4-one
  参考文献：
  名称：

  [EN] 3-SUBSTITUTED-4-PYRIMIDONE DERIVATIVES
  [FR] DERIVES 4-PYRIMIDONES SUBSTITUES EN 3

  摘要：

  由以下公式（I）表示的嘧啶酮衍生物或其盐，或其溶剂合物或水合物，可用作tau蛋白激酶1抑制剂：其中X代表CH或氮原子；R1代表一个C?1#191-C?12#191烷基基团，可以被取代；R2代表一个C?1#191-C?8#191烷基基团，可以被取代，一个可以被取代的苯环，一个可以被取代的萘环，一个可以被取代的茚环，一个可以被取代的四氢萘环，或一个可选择地取代的杂环，其中有1到4个异原子，选择自氧原子、硫原子和氮原子，并且总共有5到10个组成环的原子。

  公开号：

  WO2004055007A1
• 作为产物：
  描述：

  异烟酸 在 硫酸 、 potassium tert-butylate 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 异烟酰乙酸乙酯
  参考文献：
  名称：

  (S)-1-(4-吡啶基)-1,3-丙二醇(Ⅰ)的生物制备方法

  摘要：

  本发明提供了一种(S)‑1‑(4‑吡啶基)‑1,3‑丙二醇(Ⅰ)的生物制备方法。具体地，本发明方法包括以下步骤：(a)在反应体系中，以式Ⅳ化合物为底物，在辅酶存在下，在羰基还原酶催化下，进行不对称还原反应，从而形成式Ⅴ化合物；(b)式Ⅴ化合物经直接或分步还原得式Ⅰ化合物。

  公开号：

  CN114181984B

文献信息

• Aqueous CO₂ fixation: construction of pyridine skeletons in cooperation with ammonium cations
  作者：Shiqun Xiang、Weibin Fan、Wei Zhang、Yinghua Li、Shiwei Guo、Deguang Huang

  DOI：10.1039/d1gc02303a

  日期：——

  synthesis of fused pyridines by [2 + 2 + 1 + 1] the cycloaddition of ketones with an ammonium cation under a CO2 atmosphere. The reactions employed ammonium cation as a nitrogen source and CO2 gas as a carbon source in an aqueous solution. Monoethanolamine (MEA) was used as an additive to increase the solubility of CO2 in an aqueous solution. The scope and versatility of the method are demonstrated with 38

  通过 [2 + 2 + 1 + 1] 酮与铵阳离子在 CO 2气氛下的环加成，探索了一种简单且绿色的合成稠合吡啶的方法。该反应在水溶液中使用铵阳离子作为氮源和CO 2气体作为碳源。单乙醇胺（MEA）用作添加剂以增加CO 2在水溶液中的溶解度。该方法的范围和多功能性通过 38 个示例进行了演示。发现产品具有光敏性，并显示出作为有机光电材料的潜在应用。在实验研究的基础上提出了一种selectfluor促进的反应机理。我们的工作非常出色，因为它是一个不含金属的系统，使用 CO 2 作为碳源和 MEA 作为水性合成中的添加剂。
• [EN] 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES<br/>[FR] DERIVES DE 2,3,6-TRISUBSTITUE 4-PYRIMIDONE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004085408A1

  公开（公告）日：2004-10-07

  A pyrimidone derivative having tau protein kinase 1 inhibitory activity which is represented by formula (I) or a salt thereof, or a solvate thereof or a hydrate thereof; useful for prventive and/or therapeutic treatment of diseass such as neurodegenerative diseases (e.g. Alzheimer disease); wherein Q represents CH or nitrogen atom; R represents a C1-C12 alkyl group; the ring of Formula (I): represents piperazine ring or piperidine ring; each X independently represents a C1-C8 alkyl group, an optionally partially hydrogenated C6-C10 aryl ring, an indan ring or the like; m represents an integer of 1 to 3; each Y independently represents a halogen atom, a hydroxy group, a cyano group, a C1-C6 alkyl group or the like; n represents an integer of 0 to 8; when X and Y or two Y groups are attached on the same carbon atom, they may combine to each other to form a C2-C6 alkylene group.

  一种具有tau蛋白激酶1抑制活性的嘧啶酮衍生物，其由化学式（I）或其盐、溶剂合物或水合物表示；用于预防和/或治疗神经退行性疾病（例如阿尔茨海默病）；其中Q代表CH或氮原子；R代表C1-C12烷基基团；化学式（I）的环：代表哌嗪环或哌啶环；每个X独立地代表C1-C8烷基基团、可选择性部分氢化的C6-C10芳环、茚环或类似物；m代表1到3的整数；每个Y独立地代表卤素原子、羟基、氰基、C1-C6烷基基团或类似物；n代表0到8的整数；当X和Y或两个Y基团连接在同一碳原子上时，它们可以结合形成C2-C6烷基基团。
• [EN] HEPATITIS B CAPSID ASSEMBLY MODULATORS<br/>[FR] MODULATEURS D'ASSEMBLAGE DE CAPSIDE DE L'HÉPATITE B
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2021119081A1

  公开（公告）日：2021-06-17

  Described herein are hepatitis B capsid assembly modulators and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of hepatitis B.

  本文描述了乙型肝炎壳蛋白组装调节剂和包含该类化合物的药物组合物。这些化合物和组合物对于治疗乙型肝炎是有用的。
• Organic metal compound and process for preparing optically-active alcohols using the same
  申请人：Miki Takashi

  公开号：US20090062573A1

  公开（公告）日：2009-03-05

  The present invention provides an asymmetric reduction catalyst effective in preparing optically-active alcohol compounds having various functional groups, and a process for preparing optically-active alcohol compounds using said asymmetric reduction catalyst. The organic metal compound of the present invention is represented by the following general formula (1): wherein R 1 and R 2 may be mutually identical or different, and are an alkyl group, a phenyl group, a naphthyl group, a cycloalkyl group, or an alicyclic ring formed by binding R 1 and R 2 , which may have a substituent; R 3 is a hydrogen atom or an alkyl group; Cp is a cyclopentadienyl group, which may have a substituent, bound to M 1 via a π bond; X 1 is a halogen atom or a hydrido group; M 1 is rhodium or iridium; and * denotes asymmetric carbon.

  本发明提供了一种在制备具有各种官能团的光学活性醇化合物中有效的非对称还原催化剂，以及使用所述非对称还原催化剂制备光学活性醇化合物的方法。 本发明的有机金属化合物由以下通式(1)表示： 其中R1和R2可以相互相同或不同，并且是烷基、苯基、萘基、环烷基或由R1和R2结合形成的脂肪环环，其中可能含有取代基；R3是氢原子或烷基；Cp是环戊二烯基，可能含有取代基，通过π键与M1结合；X1是卤素原子或氢化物基团；M1是铑或铱；*表示不对称碳。
• [EN] PYRIDAZINONE DERIVATIVES AND USE THEREOF AS P2X7 RECEPTOR INHIBITORS<br/>[FR] DÉRIVÉS DE PYRIDAZINONE ET LEUR UTILISATION COMME INHIBITEURS DU RÉCEPTEUR P2X7
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2009057827A1

  公开（公告）日：2009-05-07

  Novel pyridazinone compounds of formula (I), which inhibit the purinergic P2X7 receptor and are useful for prevention, therapy and improvement of inflammatory and immunological diseases.

  翻译结果为：新型的哒嗪酮化合物，其化学公式为(I)，能够抑制嘌呤能P2X7受体，并对预防、治疗和改善炎症性和免疫性疾病有益。